Login / Signup

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Guermarie Velazquez-TorresEinav ShoshanCristina IvanLi HuangEnrique Fuentes-MatteiHarrison ParetSun Jin KimCristian Rodríguez-AguayoVictoria XieDenise BrooksSteven J M JonesA Gordon RobertsonGeorge CalinGabriel Lopez-BerensteinAnil SoodMenashe Bar-Eli
Published in: Nature communications (2018)
Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.
Keyphrases
  • crispr cas
  • poor prognosis
  • skin cancer
  • small cell lung cancer
  • squamous cell carcinoma
  • wild type
  • binding protein
  • long non coding rna